Cargando…

Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection

The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Shuo, Liang, Yingying, Kuang, Sichi, Chen, Jingbiao, Shan, Qungang, Yang, Hao, Zhang, Yao, Wang, Bin, Fowler, Kathryn J., Wang, Jin, Sirlin, Claude B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416181/
https://www.ncbi.nlm.nih.gov/pubmed/31999940
http://dx.doi.org/10.17305/bjbms.2019.4576
_version_ 1783569278943887360
author Shao, Shuo
Liang, Yingying
Kuang, Sichi
Chen, Jingbiao
Shan, Qungang
Yang, Hao
Zhang, Yao
Wang, Bin
Fowler, Kathryn J.
Wang, Jin
Sirlin, Claude B.
author_facet Shao, Shuo
Liang, Yingying
Kuang, Sichi
Chen, Jingbiao
Shan, Qungang
Yang, Hao
Zhang, Yao
Wang, Bin
Fowler, Kathryn J.
Wang, Jin
Sirlin, Claude B.
author_sort Shao, Shuo
collection PubMed
description The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study was to evaluate the accuracy of the LI-RADS version 2018 in differentiating HCC, intrahepatic cholangiocarcinoma (ICCA), and combined HCC-cholangiocarcinoma (cHCC-CCA) in Chinese patients with HBV infection. Seventy consecutive HBV-infected patients with ICCA (n = 48) or cHCC-CCA (n = 22) who underwent contrast-enhanced magnetic resonance imaging (CE-MRI) between 2006 and 2017 were enrolled along with a comparison cohort of 70 patients with HCC and CE-MRI-matched for tumor size (10–19 mm, 20–30 mm, 31–50 mm, and >50 mm). Imaging feature frequencies for each tumor type were compared using Fisher’s exact test. The classification accuracy of LR-5 and LR-M was estimated for HCC versus non-HCC (ICCA and cHCC-CCA). The interobserver agreement was good for LI-RADS categories of HCC and moderate for non-HCC. After consensus read, 66 of 70 (94%) HCCs were categorized LR-5 (including tumor in vein [TIV] with LR-5), while 42 of 48 (88%) ICCAs and 13 of 22 (59%) cHCC-CCAs were categorized LR-M (including TIV with LR-M) (p < 0.001). Thus, assignment of LR-5 provided 94% sensitivity and 81% specificity for HCC. LR-M provided 79% sensitivity and 97% specificity for non-HCC (ICCA and cHCC-CCA); and the sensitivity and accuracy were lower in differentiating HCC from non-HCC (tumor size <20 mm). LI-RADS v2018 category 5 and M reliably differentiated HBV-related HCC from ICCA. However, a substantial proportion of cHCC-CCAs were categorized LR-5 rather than LR-M. While management is controversial for these combined tumors, accurate prospective differentiation is desired for optimal treatment.
format Online
Article
Text
id pubmed-7416181
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-74161812020-08-13 Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection Shao, Shuo Liang, Yingying Kuang, Sichi Chen, Jingbiao Shan, Qungang Yang, Hao Zhang, Yao Wang, Bin Fowler, Kathryn J. Wang, Jin Sirlin, Claude B. Bosn J Basic Med Sci Research Article The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in differentiating hepatocellular carcinoma (HCC) from other hepatic malignancies has not been investigated in Chinese patients with chronic liver disease from hepatitis B virus (HBV) infection. The aim of this study was to evaluate the accuracy of the LI-RADS version 2018 in differentiating HCC, intrahepatic cholangiocarcinoma (ICCA), and combined HCC-cholangiocarcinoma (cHCC-CCA) in Chinese patients with HBV infection. Seventy consecutive HBV-infected patients with ICCA (n = 48) or cHCC-CCA (n = 22) who underwent contrast-enhanced magnetic resonance imaging (CE-MRI) between 2006 and 2017 were enrolled along with a comparison cohort of 70 patients with HCC and CE-MRI-matched for tumor size (10–19 mm, 20–30 mm, 31–50 mm, and >50 mm). Imaging feature frequencies for each tumor type were compared using Fisher’s exact test. The classification accuracy of LR-5 and LR-M was estimated for HCC versus non-HCC (ICCA and cHCC-CCA). The interobserver agreement was good for LI-RADS categories of HCC and moderate for non-HCC. After consensus read, 66 of 70 (94%) HCCs were categorized LR-5 (including tumor in vein [TIV] with LR-5), while 42 of 48 (88%) ICCAs and 13 of 22 (59%) cHCC-CCAs were categorized LR-M (including TIV with LR-M) (p < 0.001). Thus, assignment of LR-5 provided 94% sensitivity and 81% specificity for HCC. LR-M provided 79% sensitivity and 97% specificity for non-HCC (ICCA and cHCC-CCA); and the sensitivity and accuracy were lower in differentiating HCC from non-HCC (tumor size <20 mm). LI-RADS v2018 category 5 and M reliably differentiated HBV-related HCC from ICCA. However, a substantial proportion of cHCC-CCAs were categorized LR-5 rather than LR-M. While management is controversial for these combined tumors, accurate prospective differentiation is desired for optimal treatment. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2020-08 /pmc/articles/PMC7416181/ /pubmed/31999940 http://dx.doi.org/10.17305/bjbms.2019.4576 Text en Copyright: © The Author(s) (2020) http://creativecommons.org/licenses/by/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Research Article
Shao, Shuo
Liang, Yingying
Kuang, Sichi
Chen, Jingbiao
Shan, Qungang
Yang, Hao
Zhang, Yao
Wang, Bin
Fowler, Kathryn J.
Wang, Jin
Sirlin, Claude B.
Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
title Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
title_full Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
title_fullStr Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
title_full_unstemmed Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
title_short Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
title_sort diagnostic performance of li-rads version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis b virus infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416181/
https://www.ncbi.nlm.nih.gov/pubmed/31999940
http://dx.doi.org/10.17305/bjbms.2019.4576
work_keys_str_mv AT shaoshuo diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT liangyingying diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT kuangsichi diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT chenjingbiao diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT shanqungang diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT yanghao diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT zhangyao diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT wangbin diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT fowlerkathrynj diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT wangjin diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection
AT sirlinclaudeb diagnosticperformanceofliradsversion2018indifferentiatinghepatocellularcarcinomafromotherhepaticmalignanciesinpatientswithhepatitisbvirusinfection